Clinical Trials Logo

Clinical Trial Summary

Review of clinical characteristics of patients who are prescribed Repatha® and how their treatment is managed.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02770131
Study type Observational
Source Amgen
Contact
Status Completed
Phase
Start date May 4, 2016
Completion date June 30, 2021

See also
  Status Clinical Trial Phase
Completed NCT01935674 - Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels Phase 4
Completed NCT02890992 - An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Phase 2
Completed NCT00653835 - Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435) Phase 4
Recruiting NCT06008756 - MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes Phase 3
Completed NCT02585778 - Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin) Phase 3
Completed NCT00329173 - PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin. Phase 3
Completed NCT04169386 - A Study of PCSK9 Inhibitor AK102 in Healthy Subjects Phase 1
Completed NCT03510884 - An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Phase 3
Recruiting NCT06275724 - Specified Drug-use Survey of Leqvio for s.c. Injection.
Completed NCT03415178 - Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy Phase 3
Completed NCT01779687 - Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin. Phase 1
Completed NCT01617655 - Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH) Phase 3
Completed NCT00328523 - TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060) Phase 3
Completed NCT05934292 - MK-0616 (Oral PCSK9 Inhibitor) Renal Impairment Study 2 (MK-0616-020) Phase 1
Completed NCT01257971 - Non-interventional Study (NIS) to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors N/A
Completed NCT00163163 - Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women Phase 3
Completed NCT01597700 - Acotral® Versus Zetia® Ezetimibe Bioequivalance Study. Phase 1
Terminated NCT02906124 - Study to Evaluate the Safety of Repatha® in Pregnancy
Completed NCT01711749 - Rosuvastatin Calcium Bioequivalence Study - Fast Phase 1
Completed NCT02065180 - The Effect of a Red Rice and Olive Extract Nutrition Supplement on Cholesterol Levels in Patients With Metabolic Syndrome Phase 4